Cyclopharm (ASX:CYC) announced the approval of its flagship technology, Technegas, for clinical use at the National Institutes of Health.
The landmark agreement includes a formal purchase order for the NIH Clinical Centre, the world's largest dedicated clinical research hospital, with installation slated for the coming weeks.
The partnership is a significant win for Cyclopharm’s US expansion strategy, leveraging a five-year federal supply schedule agreement established in March 2025.
The framework allows for streamlined procurement across federal healthcare networks, including VA hospitals and military treatment facilities.
While Technegas is traditionally recognised for diagnosing pulmonary embolisms, its integration into the NIH’s protocol-driven environment aims to push "Beyond PE."
Researchers intend to utilise the technology's unique functional ventilation imaging—noted for high peripheral deposition and lower radiation doses compared to traditional CTPA imaging—to investigate COPD, asthma, interstitial lung disease, and oncology-related complications.
At the time of reporting, Cyclopharm's share price was $0.88.